SEC Form 3 · accession 0000899243-18-019974
Crinetics Pharmaceuticals, Inc. · CRNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wendall Wierenga
Director
Period of report
Jul 17, 2018
Accepted (ET)
Jul 17, 2018 · 8:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001658247
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 74,517 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $0.73 | holding | — | — | — | — | Dec 10, 2025 | Common Stock | 25,329 | — | D |
Explanation of responses
- F1Includes 15,830 shares of restricted stock issued upon the Reporting Person's early exercise of a stock option that remain unvested and will vest ratably over 20 months following the date of this report, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
- F2The option was initially granted with respect to 60,790 shares. 25% of the shares subject to the option vested on October 30, 2016, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. The shares subject to the option are also subject to accelerated vesting as set forth in the stock option agreement between the Issuer and the Reporting Person. The option was partially exercised with respect to 35,461 shares on April 9, 2018, which shares are included in the total number of shares of common stock owned by the Reporting Person in Table I above.